Tech Company Financing Transactions
Tasca Therapeutics Funding Round
Tasca Therapeutics, operating out of Boston, secured $52 million from Regeneron Pharmaceuticals and Invus.
Transaction Overview
Company Name
Announced On
12/10/2024
Transaction Type
Venture Equity
Amount
$52,000,000
Round
Series A
Investors
Regeneron Pharmaceuticals (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its drug discovery platform, progress its lead program, CP-383, into Phase 1/2 clinical proof-of-concept studies, and to expand its drug candidate pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
349 Newbury Street, 2nd Floor
Boston, MA 02115
USA
Boston, MA 02115
USA
Phone
Undisclosed
Website
Email Address
Overview
By harnessing the power of mass spectrometry-based proteomics to identify cancer-causing proteins that undergo a specific post-translational modification called auto-palmitoylation, Tasca is uniquely positioned to utilize previously unknown binding pockets to develop novel therapies for difficult-to-treat cancers. Tasca's lead program, CP-383, is being developed to treat patients with tumors harboring a specific genetic profile and is expected to enter clinical trials in 2025.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Milenko Cicmil
Co-Founder
David Fisher
Co-Founder
Xu Wu
Browse more venture capital transactions:
Prev: 12/10/2024: ProvLabs venture capital transaction
Next: 12/10/2024: Smardex venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records on this site come from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs